SBIR Phase I: Regulation of Hyperinflammation and Cell Survival Under Hypoxia with NELL1/N — NSF Award to NELLONE THERAPEUTICS, IN
The broader impact of this Small Business Innovation Research (SBIR) project is the development of a first-in-class therapeutic that minimizes lung damage and promotes tissue healing under the adverse environment of viral infection. The current standard of care for COVID-19 patients battling SARS-CoV-2 infection is lim
| Award title | SBIR Phase I: Regulation of Hyperinflammation and Cell Survival Under Hypoxia with NELL1/N |
|---|---|
| Award ID | 2045393 |
| Awardee | NELLONE THERAPEUTICS, INC. |
| City | KNOXVILLE |
| State | TN |
| Amount obligated | $242,342 |
| Principal investigator | Cymbeline Culiat |
| Program | SBIR Phase I |
| Start date | 04/01/2021 |
| Abstract | The broader impact of this Small Business Innovation Research (SBIR) project is the development of a first-in-class therapeutic that minimizes lung damage and promotes tissue healing under the adverse environment of viral infection. The current standard of care for COVID-19 patients battling SARS-CoV-2 infection is limited to supportive care, long hospitalization, and re-purposed anti-inflammatory or anti-viral drugs. Many survivors suffer long-term lung scarring that reduces respiratory functio |
| Source | NSF Awards |
$799/mo
Try NSFGrants →